Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Kevin J. Hamblett(Seagen (United States)), Joseph A. Francisco(Seagen (United States)), Damon L. Meyer(Seagen (United States)), Charles G. Cerveny(Seagen (United States)), Roger F. Zabinski(Seagen (United States)), Kim M. Kissler(Seagen (United States)), Dana F. Chace(Seagen (United States)), Anastasia K. Kopcha(Seagen (United States)), Peter D. Senter(Seagen (United States)), Michael Sun(Seagen (United States)), Joel S. Lenox(Seagen (United States)), Starr X. Bernhardt(Seagen (United States))
Cited by 1,212
Related Papers
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
Arming antibodies: prospects and challenges for immunoconjugates
|Nature Biotechnology|2005|1k
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
|Blood|2003|918
Antibody–drug conjugates come of age in oncology
|Nature Reviews Drug Discovery|2023|772
Antibody-Drug Conjugates in Cancer Therapy
|Annual Review of Medicine|2012|763